These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 12532425)

  • 1. Clinical course of bladder neoplasms and single nucleotide polymorphisms in the CDKN2A gene.
    Sakano S; Berggren P; Kumar R; Steineck G; Adolfsson J; Onelöv E; Hemminki K; Larsson P
    Int J Cancer; 2003 Mar; 104(1):98-103. PubMed ID: 12532425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma.
    Rebouissou S; Hérault A; Letouzé E; Neuzillet Y; Laplanche A; Ofualuka K; Maillé P; Leroy K; Riou A; Lepage ML; Vordos D; de la Taille A; Denoux Y; Sibony M; Guyon F; Lebret T; Benhamou S; Allory Y; Radvanyi F
    J Pathol; 2012 Jul; 227(3):315-24. PubMed ID: 22422578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CDKN2a common variants: 148 Ala/Thr and 500 C/G in 3' UTR, and their association with clinical course of melanoma.
    Lamperska KM; Przybyła A; Kycler W; Mackiewicz A
    Acta Biochim Pol; 2007; 54(1):119-24. PubMed ID: 17351674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer.
    Berggren de Verdier PJ; Kumar R; Adolfsson J; Larsson P; Norming U; Onelöv E; Wijkström H; Steineck G; Hemminki K
    Scand J Urol Nephrol; 2006; 40(5):363-9. PubMed ID: 17060081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy.
    Sakano S; Wada T; Matsumoto H; Sugiyama S; Inoue R; Eguchi S; Ito H; Ohmi C; Matsuyama H; Naito K
    Br J Cancer; 2006 Sep; 95(5):561-70. PubMed ID: 16880786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The mechanism of p16 gene inactivation in human bladder transitional cell carcinoma].
    Wu Y; Wu H; Ma T; Wu C
    Zhonghua Bing Li Xue Za Zhi; 1999 Feb; 28(1):39-41. PubMed ID: 11869511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR.
    Berggren P; Kumar R; Sakano S; Hemminki L; Wada T; Steineck G; Adolfsson J; Larsson P; Norming U; Wijkström H; Hemminki K
    Clin Cancer Res; 2003 Jan; 9(1):235-42. PubMed ID: 12538475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare.
    Kumar R; Smeds J; Berggren P; Straume O; Rozell BL; Akslen LA; Hemminki K
    Int J Cancer; 2001 Nov; 95(6):388-93. PubMed ID: 11668523
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RUNX3 methylation as a predictor for disease progression in patients with non-muscle-invasive bladder cancer.
    Yan C; Kim YW; Ha YS; Kim IY; Kim YJ; Yun SJ; Moon SK; Bae SC; Kim WJ
    J Surg Oncol; 2012 Mar; 105(4):425-30. PubMed ID: 22311819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The predictive value of GSTT1 polymorphisms in predicting the early response to induction BCG therapy in patients with non-muscle invasive bladder cancer.
    Kang HW; Tchey DU; Yan C; Kim WT; Kim YJ; Yun SJ; Lee SC; Choi YH; Kim IY; Kim WJ
    Urol Oncol; 2014 May; 32(4):458-65. PubMed ID: 24411789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma.
    Breyer J; Wirtz RM; Erben P; Worst TS; Stoehr R; Eckstein M; Bertz S; Sikic D; Denzinger S; Burger M; Hartmann A; Otto W;
    Clin Genitourin Cancer; 2018 Aug; 16(4):248-256.e2. PubMed ID: 29525349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter hypermethylation in tumour suppressor genes shows association with stage, grade and invasiveness of bladder cancer.
    Jarmalaite S; Jankevicius F; Kurgonaite K; Suziedelis K; Mutanen P; Husgafvel-Pursiainen K
    Oncology; 2008; 75(3-4):145-51. PubMed ID: 18824877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas.
    Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C
    Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of rs8444 polymorphism in the LASS2 3'-UTR and bladder cancer risk in Chinese population.
    Huang Y; Wang H; Fu S; Luan T; Zuo Y; Li N; Ding M; Chen Y; Wang J
    Eur J Cancer Prev; 2020 Jul; 29(4):329-337. PubMed ID: 31577563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Specific p53 gene mutations in urinary bladder epithelium after the Chernobyl accident.
    Yamamoto S; Romanenko A; Wei M; Masuda C; Zaparin W; Vinnichenko W; Vozianov A; Lee CC; Morimura K; Wanibuchi H; Tada M; Fukushima S
    Cancer Res; 1999 Aug; 59(15):3606-9. PubMed ID: 10446970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer.
    Gu J; Zhao H; Dinney CP; Zhu Y; Leibovici D; Bermejo CE; Grossman HB; Wu X
    Clin Cancer Res; 2005 Feb; 11(4):1408-15. PubMed ID: 15746040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 mutations in bladder carcinoma cell lines.
    Cooper MJ; Haluschak JJ; Johnson D; Schwartz S; Morrison LJ; Lippa M; Hatzivassiliou G; Tan J
    Oncol Res; 1994; 6(12):569-79. PubMed ID: 7787250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
    Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
    Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 Gene mutations in superficial bladder cancer.
    Lorenzo Romero JG; Salinas Sánchez AS; Giménez Bachs JM; Sánchez Sánchez F; Escribano Martínez J; Hernández Millán IR; Segura Martín M; Virseda Rodríguez JA
    Urol Int; 2004; 73(3):212-8. PubMed ID: 15539839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Urokinase Gene 3'-UTR T/C polymorphism with bladder cancer.
    Manchanda PK; Bid HK; Mittal RD
    Urol Int; 2006; 77(1):81-4. PubMed ID: 16825821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.